ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2013
Imaging tumor burden in the brain with 89Zr-transferrin.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Synthesis and Application Evaluation of the Novel Nanocluster MnS@Tf for Tumor Management.Pharmaceutics · 2026Article
- Design and Preclinical Evaluation of aACS omega · 2025Article
- Evaluation of differentScientific reports · 2022Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Exploring Serum Transferrin Regulation of Nonferric Metal Therapeutic Function and Toxicity.Inorganics · 2020Article
- A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Translational molecular imaging in exocrine pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2018Review
- Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.JCI insight · 2018Article
- NoninvasiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.Molecular cancer research : MCR · 2017Article
- Noninvasive Measurement of mTORC1 Signaling withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Investigation of the complexation ofDalton transactions (Cambridge, England : 2003) · 2017Article
- Siderophores for molecular imaging applications.Clinical and translational imaging · 2017Review
- A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry.Molecular therapy. Nucleic acids · 2016Article
- Article
- Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles.Chemical science · 2015Article
- Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Inorganic chemistry · 2014Article
- (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.Molecules (Basel, Switzerland) · 2013Review
- Non-invasive in vivo imaging of near infrared-labeled transferrin in breast cancer cells and tumors using fluorescence lifetime FRET.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledA noninvasive technology that indiscriminately detects tumor tissue in the brain could substantially enhance the management of primary or metastatic brain tumors. Although the documented molecular heterogeneity of diseases that initiate or eventually deposit in the brain may preclude identifying a single smoking-gun molecular biomarker, many classes of brain tumors are generally avid for transferrin. Therefore, we reasoned that applying a radiolabeled derivative of transferrin ((89)Zr-labeled transferrin) may be an effective strategy to more thoroughly identify tumor tissue in the brain, regardless of the tumor's genetic background.
methodsTransferrin was radiolabeled with (89)Zr, and its properties with respect to human models of glioblastoma multiforme were studied in vivo.
resultsIn this report, we show proof of concept that (89)Zr-labeled transferrin ((89)Zr-transferrin) localizes to genetically diverse models of glioblastoma multiforme in vivo. Moreover, we demonstrate that (89)Zr-transferrin can detect an orthotopic lesion with exceptional contrast. Finally, the tumor-to-brain contrast conferred by (89)Zr-transferrin vastly exceeded that observed with (18)F-FDG, currently the most widely used radiotracer to assess tumor burden in the brain.
conclusionThe results from this study suggest that (89)Zr-transferrin could be a broadly applicable tool for identifying and monitoring tumors in the brain, with realistic potential for near-term clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.